UNSPSC 51313432: Pemirolast potassium

This classification denotes a mast cell stabilizer with the molecular formula C10H7N6O.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 497A17OUUE, chemically known as 9-methyl-3-(1h-tetrazol-5-yl)-4h-pyrido(1,2-a)pyrimidin-4-one, potassium salt but more generally known as pemirolast potassium, which bears US NIH Compound Identifier 57696. European Medicines Agency schedules Pemirolast potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03670MIG.

Most nations, for tariff and trade purposes, schedule pemirolast potassium under HS 29335995 and SITC 51576. As of Q4 2014, PEMIROLAST POTASSIUM remains US FDA's Preferred Term for this commodity. Pemirolast potassium bears US NLM identifiers UMLS ID C0872971 and NCI Concept Code C47654. SMILES: CC1CCCN2C1NCC(C2=O)C3[N-]NNN3.[K+].

UNSPSC 51313432 Pemirolast potassium is a Commodity code that nominally covers a specific ophthalmic antihistamine agent, but recent state and local solicitations tagged to this code show minimal alignment with that scope. The three recent opportunities span naloxone procurement (emergency overdose reversal), direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical and over-the-counter product supply contracts — none of which are pemirolast potassium or closely related products. The code appears to reflect broad pharmaceutical purchasing activity rather than the specific drug named in the taxonomy. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving multiple states including Oregon). The mix spans tactical single-jurisdiction buys, exploratory state-level market research, and multi-jurisdictional cooperative contracts.

Recent activity clusters in Florida, Texas, and Minnesota, with broader multi-state reach through MMCAP's cooperative vehicle. Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: the due date appears to be a data error and predates the posting date). The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program — a preliminary market-intelligence phase without binding timelines or budget commitments. The Minnesota Multistate Cooperative Purchasing Alliance posted RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline, establishing multiple contracts for generic pharmaceuticals and OTC products priced competitively (75 percent weight) with a two-year term and optional extensions. The code shows recent activity but poor nominal alignment; vendors should verify whether opportunities are genuinely tagged to pemirolast potassium procurement or represent broader pharmaceutical taxonomy misclassification before pursuing.